Adenoidectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Adenoidectomy is the surgical removal of the adenoids — the lymphoid tissue (adenoid pad) located in the posterior nasopharynx, behind the nasal cavity and above the soft palate. The adenoids form part of Waldeyer's ring of lymphoid tissue and play an immune surveillance role during early childhood, reaching peak size around 5–7 years of age before naturally regressing through adolescence. When adenoids become chronically enlarged (adenoid hypertrophy) or repeatedly infected (adenoiditis), they can obstruct the nasopharyngeal airway, block the Eustachian tube openings, and serve as a reservoir for chronic infection — producing significant morbidity including sleep-disordered breathing, chronic ear disease, nasal obstruction, and mouth breathing.

Adenoidectomy is one of the most commonly performed surgical procedures in children worldwide. It is frequently combined with tonsillectomy (adenotonsillectomy, or T&A) for paediatric obstructive sleep apnoea (OSA) and with myringotomy with ventilation tube (grommet) insertion for chronic otitis media with effusion (OME, or 'glue ear'). Modern adenoidectomy is performed transorally under general anaesthesia using curettage (curette), suction diathermy electrocautery (the most widely used contemporary technique due to minimal bleeding), powered microdebrider shaving, or endoscopic direct vision approaches that have largely replaced the historically 'blind' curettage technique.

Endoscopic-assisted adenoidectomy, performed with a rigid nasoendoscope or nasopharyngoscope passed through the nose or mouth, provides direct visualisation of the adenoid pad and Eustachian tube orifices, enabling complete adenoid removal under vision while protecting adjacent critical structures — a significant advance over traditional blind curettage.

Adenoidectomy is indicated for several specific conditions in which adenoid hypertrophy or chronic adenoiditis is established as a causative or contributing factor:

Obstructive sleep apnoea (OSA) and sleep-disordered breathing in children: Adenotonsillar hypertrophy is the most common cause of paediatric OSA, affecting 2–3% of children. Symptoms include habitual snoring, witnessed apnoeas, laboured breathing during sleep, restless sleep, nocturnal enuresis, morning headaches, and behavioural disturbances including hyperactivity and attention deficit — which may be misdiagnosed as ADHD. Adenotonsillectomy (combined adenoidectomy and tonsillectomy) is the first-line surgical treatment for paediatric OSA, resolving OSA in 60–80% of children without obesity.

Chronic otitis media with effusion (OME — glue ear): Adenoid tissue adjacent to the Eustachian tube openings contributes to Eustachian tube dysfunction and middle ear fluid accumulation. Adenoidectomy, typically combined with grommet insertion, improves middle ear ventilation, reduces recurrence of glue ear, and improves hearing — particularly important during the critical language development period (ages 1–5 years). The NIHR TARGET randomised trial demonstrated that adenoidectomy combined with grommet insertion provides significantly better hearing outcomes at 1 year compared to grommet alone in children with recurrent OME.

Recurrent acute otitis media (RAOM): Children suffering 4 or more episodes of acute bacterial middle ear infection per year may benefit from adenoidectomy to remove the chronic bacterial reservoir in adenoid tissue. Adenoidectomy reduces recurrent otitis media episodes by approximately 30–40% in evidence-based studies.

Nasal obstruction and chronic rhinosinusitis in children: Adenoid hypertrophy causing persistent mouth breathing, snoring without OSA, chronic nasal discharge, and sleep disturbance. Chronic rhinosinusitis in children unresponsive to medical therapy is increasingly managed with adenoidectomy as a component of the surgical treatment plan, as the adenoid may harbour biofilm-forming bacteria that drive sinusitis recurrence.

Adenoidectomy is most commonly performed in children aged 3–12 years, though it can be performed in older children, adolescents, and adults with persistent symptoms. Candidacy for adenoidectomy is established by an otolaryngologist (ENT surgeon) based on symptom severity, duration, response to conservative therapy, and endoscopic or imaging evidence of adenoid hypertrophy.

For OSA: Formal diagnosis with overnight polysomnography (sleep study) or home oximetry is performed in ambiguous cases. Children with moderate-to-severe OSA (apnoea-hypopnoea index >10 events/hour) are prioritised for early surgery. Children with mild OSA may be observed or treated with nasal steroids before surgery.

For glue ear: Adenoidectomy is indicated when OME has been present for 3 months or longer with hearing loss ≥25 dB, particularly during the language development period. Two failed courses of antibiotic therapy before surgical referral is typical.

Contraindications to adenoidectomy include: submucous cleft palate (adenoid tissue may be important for palatal competence — velopharyngeal insufficiency with hypernasal speech can result from adenoidectomy in these patients; cleft palate must be excluded by palatal examination before surgery), active acute upper respiratory infection (surgery deferred 2–4 weeks), uncorrected coagulopathy (INR normalised preoperatively; aspirin/NSAIDs stopped 7–10 days before), and haemoglobin below safe surgical levels requiring correction. Preoperative assessment includes full blood count, bleeding time (if indicated), and anaesthetic fitness assessment. Flexible nasendoscopy or lateral neck X-ray quantifies adenoid size and choanal narrowing.

Modern adenoidectomy is performed transorally under general anaesthesia with the patient in the Rose position (supine, head extended, mouth opened with a mouth gag such as Boyle-Davis). The nasopharynx is exposed using a mirror or endoscope through the mouth or nose.

Suction diathermy electrocautery: The most widely adopted contemporary technique. A suction diathermy probe uses monopolar or bipolar cautery to remove adenoid tissue with simultaneous haemostasis. It allows controlled, precise tissue ablation with excellent visibility and minimal blood loss. The suction tip continuously evacuates blood and smoke during cauterisation, improving visualisation.

Powered microdebrider: A motorised rotating-blade instrument with continuous suction that shaves adenoid tissue precisely under endoscopic visualisation. Provides excellent tissue removal with minimal thermal spread and is increasingly preferred at paediatric ENT centres with endoscopic equipment, allowing direct vision adenoidectomy without the blind-curettage risk of Eustachian tube injury.

Curettage: The traditional technique using a ring curette passed behind the soft palate to scrape the adenoid tissue. Now largely replaced by suction diathermy or microdebrider at well-equipped centres due to higher bleeding rates and inability to visualise the operative field directly. Still used in resource-limited settings where it remains effective.

Endoscopic adenoidectomy: Transnasal or transoral rigid endoscope provides direct vision of the adenoid pad, posterior choanae, and Eustachian tube orifices. This approach significantly reduces the risk of incomplete adenoid removal (leading to regrowth and symptom recurrence) and avoids inadvertent injury to the Eustachian tube openings. Studies demonstrate lower recurrence rates and lower complication rates compared to traditional blind curettage.

Coblation adenoidectomy: Radiofrequency energy applied in the presence of saline creates a plasma field that removes tissue at low temperatures (~40–70°C), reducing thermal injury to adjacent tissue and theoretically improving healing. Increasingly available at specialist centres but evidence comparing it to suction diathermy is mixed.

Combined procedures: Adenoidectomy is frequently combined with tonsillectomy for OSA or recurrent tonsillitis (adenotonsillectomy), or with myringotomy and grommet insertion for OME, performed in the same anaesthetic episode.

Adenoidectomy is highly effective for its primary indications. For paediatric obstructive sleep apnoea, adenotonsillectomy resolves OSA (normalises the AHI) in 60–80% of non-obese children, with the remainder showing significant improvement in sleep-disordered breathing severity. Behavioural outcomes — attention, hyperactivity, and neurocognitive function — improve significantly after adenotonsillectomy for OSA in multiple randomised controlled trials (CHAT trial, USA), with caregiver-reported quality of life improving in over 85% of children.

For chronic otitis media with effusion, adenoidectomy combined with grommet insertion results in hearing improvement to normal levels (≤20 dB) in 85–90% of children at 12 months. The NIHR TARGET trial demonstrated that adenoidectomy + grommet produces significantly better hearing outcomes than grommet insertion alone at 1 year, with fewer re-operations. Recurrence of glue ear requiring further surgery is reduced by 40–50% after adenoidectomy.

For recurrent acute otitis media, adenoidectomy reduces annual otitis media episodes by an average of 30–40%, reducing antibiotic courses, ear pain burden, and time lost from school and parental work. For nasal obstruction, adenoidectomy improves objective nasal airflow and resolves mouth breathing in the majority of appropriately selected children, with improvement in sleep quality, feeding, and speech development. Long-term quality of life improvement following adenoidectomy is consistently high across published outcome studies.

Adenoidectomy is a generally safe procedure with a low complication rate in healthy children. The most clinically significant complication is postoperative haemorrhage.

Primary haemorrhage (within 24 hours): occurs in 0.5–1.5% of adenoidectomies, requiring return to theatre for cauterisation or surgical control. This risk is minimised by meticulous haemostasis during the primary procedure and the use of suction diathermy techniques. Secondary haemorrhage (day 5–10, corresponding to eschar separation): slightly less common than primary bleeding, occurring in approximately 0.5–1% of patients; may present as blood-stained saliva or frank bleeding from the mouth. All adenoidectomy patients are given clear advice to return to hospital immediately for any bleeding post-discharge.

Velopharyngeal insufficiency (VPI): The most serious specific complication of adenoidectomy, occurring in approximately 1 in 1,500–3,000 cases, manifesting as hypernasal speech because the soft palate cannot now adequately close against the posterior pharyngeal wall in the absence of the adenoid pad. Most cases are transient (resolving within weeks as the palate adapts), but persistent VPI requires speech therapy and occasionally surgical correction (pharyngoplasty). Risk is highest in patients with submucous cleft palate (hence the critical importance of preoperative examination).

Nasal voice change: Transient hyponasality (nasal stuffiness voice) is common in the first 1–2 weeks while edema resolves; not usually persistent. Eustachian tube injury: with curettage, inadvertent trauma to the Eustachian tube orifices can cause scarring and worsening of Eustachian tube function — minimised by endoscopic technique. Anaesthetic risks appropriate for age: in experienced paediatric anaesthetic centres, serious anaesthetic complications are rare. Airway management in young children with OSA requires particular expertise. Nasal regurgitation of liquids during swallowing: occasionally occurs transiently after adenoidectomy, resolving within days as swallowing function adapts.

Adenoidectomy is performed as day surgery in the majority of cases — patients are discharged home the same day once they have recovered from anaesthesia, taken oral fluids, and met discharge criteria. Overnight admission is arranged for children under 3 years of age, those with severe OSA (SpO2 nadir <80% or AHI >20 on preoperative sleep study) requiring post-operative oxygen monitoring, or those with significant comorbidities.

Post-operative pain is typically mild to moderate, managed with regular paracetamol (acetaminophen) and ibuprofen for 5–7 days. Codeine is avoided in children due to variable metabolism and risk of respiratory depression. Diet is soft and cool for the first 5–7 days — ice cream, cold yoghurt, smoothies. Normal diet is resumed as tolerated. School return is typically at 7–10 days. Contact sports or activities with risk of Valsalva (nose blowing) are avoided for 2 weeks.

Follow-up appointments depend on the associated procedure: for adenoidectomy with grommet insertion, review at 6–8 weeks includes audiological assessment (pure tone audiometry) to confirm hearing improvement and grommet position on otoscopy. Grommets are reviewed annually until extrusion. For adenoidectomy for OSA, a post-operative sleep study at 3–6 months confirms resolution of OSA — particularly important in obese children or those with Down syndrome where residual OSA despite surgery is common. Parents should be counselled that while adenoids do not typically regrow completely, partial adenoid tissue re-growth occurs in approximately 10% of cases within 2–3 years, more commonly in younger children operated before age 3. Recurrence of symptoms warrants reassessment.

Adenoidectomy costs differ substantially between healthcare systems. In the United States, adenoidectomy (including outpatient surgical facility, anaesthesia, and surgeon fees) costs $5,000–$12,000 without insurance. Combined adenotonsillectomy costs $8,000–$18,000. With insurance, out-of-pocket costs depend on deductibles and plan type but may still run to $1,500–$4,000 for families with high-deductible plans.

In the United Kingdom, adenoidectomy is routinely available on the NHS without direct patient cost where clinical criteria are met, though waiting times may be 3–12 months depending on region. Private UK ENT surgery costs £2,500–£5,000 for adenoidectomy alone; £4,000–£8,000 for adenotonsillectomy.

In India, adenoidectomy at leading private hospitals (Apollo, Fortis, Manipal, Medanta) costs $800–$2,500, with endoscopic adenoidectomy available within the same range. Combined adenotonsillectomy costs $1,200–$3,500, representing savings of 70–85% versus US prices. Thailand (Samitivej, Bumrungrad) charges $1,200–$3,000. Turkey charges €1,000–€2,500. Singapore charges SGD 3,000–8,000. These facilities offer paediatric-specialist ENT surgeons, dedicated paediatric anaesthesia, and child-friendly perioperative environments. For families from countries with high private healthcare costs, medical tourism for elective adenoidectomy or adenotonsillectomy may be cost-effective when combined with comprehensive travel and accommodation planning.

Non-surgical management of adenoid hypertrophy may defer or occasionally avoid the need for adenoidectomy in selected patients. Intranasal corticosteroid sprays (mometasone furoate, fluticasone propionate) reduce adenoid volume by 15–25% in randomised trials and improve nasal airflow and sleep-disordered breathing scores — making them a first-line medical option for mild-to-moderate adenoid hypertrophy before proceeding to surgery. Courses of 3–6 months are typically prescribed before surgical review.

Antibiotic therapy for adenoiditis: Prolonged low-dose prophylactic antibiotics (trimethoprim-sulfamethoxazole or azithromycin) are sometimes used for recurrent otitis media to reduce the frequency of bacterial episodes, potentially delaying or reducing the need for adenoidectomy in carefully selected children. Watchful waiting: For mild OME not affecting hearing significantly, watchful waiting for 3 months before intervention is appropriate — glue ear resolves spontaneously in approximately 50% of cases within 3 months. For mild OSA without hypoxaemia, a trial of medical management (intranasal steroids, montelukast) may defer surgery. Continuous positive airway pressure (CPAP): For children with severe OSA who are not surgical candidates or who have residual OSA after adenotonsillectomy, CPAP delivered through a paediatric mask is an effective alternative, though adherence in young children is challenging. Weight loss in obese children with OSA before adenotonsillectomy improves surgical outcomes.